Telomir Pharmaceuticals, Inc. (TELO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on October 20, 2025, covering events occurring on October 17, 2025. Telomir Pharmaceuticals, Inc., an emerging growth company incorporated in Florida, announced the execution of a binding Letter of Intent (LOI) to acquire TELI Pharmaceuticals, Inc. (TELI). The transaction aims to consolidate worldwide intellectual property and development rights for Telomir-1, the Company's lead investigational oral epigenetic therapy for cancer and age-related diseases.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or existing debt levels. The primary financial terms disclosed relate to the proposed transaction:
- Transaction Structure: Stock-for-stock exchange; the specific exchange ratio is to be determined by an independent third-party valuation.
- Shareholder Contributions: Certain TELI shareholders have agreed to contribute up to $5 million in cash to Telomir Pharmaceuticals.
- Contribution Schedule: $1 million at closing, $2 million upon FDA acceptance of an Investigational New Drug (IND) application, and $2 million upon initiation of a Phase 1/2 study.
- Issuance Terms: Shares corresponding to the $4 million in milestone contributions will be allocated at closing but issued only upon receipt of payments. The transaction closing is not contingent on these milestone funds.
Material Changes
The material change reported is the entry into a definitive agreement to acquire TELI Pharmaceuticals. This action consolidates U.S. and ex-U.S. rights to Telomir-1 within a single public entity, simplifying global development and partnership efforts. No prior comparable period financial data is provided in this filing to assess year-over-year changes.
Outlook, Risks, and Contingencies
Outlook: Management states the transaction positions the company for global market expansion and value growth by unifying global IP rights.
Contingencies and Risks: Completion of the transaction is subject to:
- Mutually satisfactory due diligence.
- Final board and stockholder approvals.
- Regulatory clearances.
- Execution of definitive documentation.
The LOI includes a six-month lockup period on Telomir shares issued to TELI shareholders and customary provisions for confidentiality and exclusivity.
Key Facts for Investor Verification
- Verify the independent third-party valuation process to determine the final stock exchange ratio.
- Confirm the specific identities of the TELI shareholders committing the $5 million cash contribution.
- Monitor the timeline for FDA IND acceptance and Phase 1/2 study initiation to trigger milestone payments.
- Review the full text of the Letter of Intent (Exhibit 10.1) for detailed terms regarding the lockup period and termination rights.
- Assess the impact of the stock-for-stock exchange on existing shareholder dilution once the ratio is finalized.